BURLINGTON, Mass., June 28, 2017 /PRNewswire/ -- Decision Resources Group finds that practitioners prescribing inhaled therapies prefer simpler devices. Although the diverse array of drug/device combinations available allows them to match the prescription to the needs of a particular patient, multiple factors, including device type, number of steps, and positioning within a drug/device franchise, influence prescribing decisions.

Decision Resources Group Logo. (PRNewsFoto/Decision Resources Group)

To learn more about this report, please visit our website: http://bit.ly/2tXI2CE

Other key findings from the Special Report on Asthma and COPD Devices:

  • Practitioners typically indicate that their prescribing decisions are guided, but not dominated, by device considerations.
  • The emergence of generics could have a significant impact on the asthma and COPD market, but the influence of device may cause practitioners to prefer branded therapies with which they are already familiar.
  • Patient-related factors, including the number of steps required, are considered when selecting an inhaled therapy, along with clinical factors including molecule efficacy and lung deposition.
  • Although many currently available devices are rated highly on individual factors, surveyed pulmonologists indicate a high level of unmet need for novel handheld inhalers,

Comments from Decision Resources Group Analyst Kristine Mackin:

  • "In interviews, it's clear that pulmonologists and nurse practitioners have a preference for certain devices, especially those that are easy to teach, but they also express willingness to work with patients to select a device that meets their needs."
  • "Pulmonologists express a clear preference for a device that delivers improved deposition, but are skeptical of lung deposition claims, especially those made in the absence of clinical trial evidence showing improved patient outcomes."

About Decision Resources Group
DRG, a subsidiary of Piramal Enterprises Ltd., is the premier source for global healthcare data and market intelligence. A trusted partner for over 20 years, DRG helps companies competing in the global healthcare industry make informed business decisions. Organizations committed to the developing and delivering life-changing therapies to patients rely on DRG's in-house team of expert healthcare analysts, data scientists, and consultants for critical guidance. DRG products and services, built on extensive data assets and delivered by experts, empower organizations to succeed in complex healthcare markets.

Media contact:

Decision Resources Group
Whitney Goldstein

SOURCE Decision Resources Group

Survey Shows Intensifying Focus on Cost and Demonstration of Value in Increasingly Competitive Orphan Drug Space

View Now